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Summary In a population-based mammography screening, 129 731 examinations were carried out among 36 000 women aged 40-74 in the
city of Turku, Finland, in the period 1987-94. Women older than 50 were screened at 2-year intervals, and those younger than 50 at either 1-
year or 3-year intervals, depending on their year of birth. Screen-detected breast cancers numbered 385 and, during the same time period,
154 women were diagnosed with breast cancer outside screening in the same age group in the same city, and 100 interval cancers were
detected. Two hundred and fifty (67%) of the screen-detected cancers were of post-surgical stage compared with 45 (45%) of the interval
cancers and 52 (34%) of the cancers found outside screening (P<0.0001). However, among women aged 40-49 the frequency of stage
cancers did not differ significantly among screen-detected cancers, interval cancers and cancers found outside screening (50%, 42% and
44% respectively; P=0.73). Invasive interval cancers were more frequent among women aged 40-49 if screening was done at either 1-year
(27%) or 3-year intervals (39%) than in older women screened at 2-year intervals (18%; P=0.08 and P=0.0009 respectively). Even if adjusted
forthe primary tumour size, screen-detected cancers had smaller S-phase fractions than interval cancers or control cancers (P=0.01), but no
difference in the S-phase fraction size was found between cancers of women younger than 50 and those older than this (P=0.13). We
conclude that more interval cancers were found among women younger than 50 than among those older than 50 and that this could not be
explained by the rate of cancer cell proliferation.
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Mammography is currently used for population-based mass
screening ofbreast cancer in several countries because it can detect
asymptomatic breast cancer at an early stage when dissemination
of cancer is still unlikely. Small asymptomatic cancers can be
detected by mammography not only among women older than 50
years, but also among younger women aged 40-49 years (Peeters
et al, 1989; Ikeda et al, 1992; Moss et al, 1993; Burhenne et al,
1994). In a meta-analysis screening mammography reduced breast
cancer mortality by 26% (95% CI 17-34%) in women aged 50-74
but did not significantly reduce breast cancer mortality in women
aged 40-49 (Kerlikowske et al, 1995). However, analysis of
randomized trials on mammography screening concluded that, if
the Canadian National Breast Screening Study was excluded from
the analysis, a statistically significant benefit of 23% was present,
in favour ofthe screened women (Smart et al, 1995). It is debatable
whether or not population-based mass screening should be carried
out among women younger than 50 (Fletcher et al, 1993; Kaluzny
et al, 1994).
Although a shorter screening interval than 2 years has been
recommended and used by some (Morrison et al, 1988; Tabaret al,
1995), a meta-analysis of studies in which mammography
screening at various intervals was compared with no screening
failed to show that screening at 12-month intervals is more benef-
ical than screening at 18- to 33-month intervals among women
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older than 50 (Kerlikowske et al, 1995). Hence, a screening
interval of 2 years was recommended for women aged 50-74.
Similarly, among women aged 40-49 screening at 12-month inter-
vals does not appear to be more effective than screening at 18- to
33-month intervals, but the meta-analysis included only two
studies in which women aged 40-49 had been screened annually
(Kerlikowske et al, 1995). However, different screening intervals
have never been compared in a randomized fashion. It has been
suggested that breast cancers among women younger than 50
years grow faster than those in older women, which might lead to
more frequent interval cancers in this age group, unless the
screening interval is short (Tabar et al, 1995).
Premenopausal women have a long life expectancy, and mass
screening in this age group might lead to many years of life saved.
On the other hand, premenopausal women have more functional
breast tissue than post-menopausal women (Haagensen et al, 1971),
and mammography screening may be less effective in this age group,
leading to a greater numberofinterval cancers and increased cost.
A population-based mammography screening programme was
started in 1987 among women aged 40-74 in the city of Turku,
Finland. In the age group 40-49 women were screened at either 1-
or 3-year intervals based on their calendar year of birth, which
provides an opportunity to examine the effect of the screening
interval on the efficacy of screening among premenopausal
women. We were able to compare, in this well-defined population,
the histological and biological properties of the screen-detected
cancers with cancers detected between the screening rounds
among the screened women (interval cancers) and cancers found
outside screening among those women who either refused
screening or had breast cancer detected before they were screened
762Mammographyscreening interval andintervalcancers 763
Table 1 Frequency of interval cancers
Screening Invasive Invasive Invasive Invasive
interval screen- interval screen- interval
detected cancers detected cancers
cancers and DCISa cancers
and DCISa
n (%) n (%) n (%) n (%)
Age 40-49 years
1-Year 52 (75) 17 (25)b 43 (73) 16 (27)c
3-Year 32 (65) 17 (35)d 27 (61) 17 (39)e
Age 50-74 years
2-Year 338 (83) 70 (17) 315 (82) 67 (18)
aDCIS, ductal carcinoma in situ. bP=0.13 compared with age group 50-74
years. cP=0.08 compared with age group 50-74 years. dp=0.003 compared
with age group 50-74 years. ep=0.0009 compared with age group 50-74
years.
Table 2 The frequency of pTl NOMO (post-surgical stage 1) cancer in a
population of 36 000 women aged 40-74 years during population-based
screeninga
Screen- Clinical Interval P
detected cancers cancers
cancers
n (%) n (%) n (%)
Age 40-74 years
Stage 250 (67) 52 (34) 45 (45)
Stage Il-IV 123 (33) 99 (66) 54 (55) < 0.0001
Age 40-49 years
Stage 35 (50) 20 (44) 14 (42)
Stage Il-IV 35 (50) 25 (56) 19 (58) 0.73
Age 50-74 years
Stage 215 (71) 32 (30) 31 (47)
Stage Il-IV 88 (29) 74 (70) 35 (53) <0.0001
Sixteen cases had missing data.
for the first time (clinical cancers). The results suggest that
screening carried out at 1-year or 3-year intervals among women
aged less than 50 is less effective than screening carried out at 2-
year intervals among older women.
MATERIAL AND METHODS
Population-based mass mammography screening was started in
the city of Turku, south-western Finland, in 1987. The city has a
population of about 160 000, of which about 36 000 are female
inhabitants aged 40-74. An invitation to screening was mailed to
women aged 50 or more at 2-year intervals, to those aged less than
50 and born on an even-numbered calendar year annually and to
those aged less than 50 and born on an odd-numbered year every
third year.
Mammography was performed at one of the two screening
centres. At the centre, the women completed a questionnaire on
possible symptoms or signs related to breast cancer, and a
mammogram was taken using the craniocaudal and oblique lateral
projections from both breasts. All mammograms were read by two
experienced radiologists. In cases of suspected breast cancer, new
magnified mammograms were taken, and an ultrasound examina-
tion with a needle biopsy was carried out before a surgical biopsy.
All visits, examinations performed and the histopathological find-
ings were recorded by a nurse in the Turku mammography
screening database.
In the period 1987-94, 129 731 bilateral mammography exami-
nations were carried out at the two screening centres, with 87.6% of
the 148 047 invited women attending the first or the subsequent
screening rounds. Cancers found after a negative mammogram
between two subsequent screens are called interval cancers, and
cancers found in the period 1987-94 in the same female target
population outside screening are called clinical cancers. The clinical
cancers were either found among those who refused screening or
among those aged40-74years butwho hadtheirbreastcancerdiag-
nosed before the first screening took place in the period 1987-94.
Staging was determined according to the UICC TNM classifica-
tion (Hermanek and Sobin, 1987). The primary tumour size was
measured from the surgical specimen.
Histology
All histological samples were re-examined and reclassified by a
pathologist with a large experience in breast cancer pathology
(ST) from haematoxylin-eosin- and van Gieson-stained slides.
The histological typing and grading were carried out with a slight
modification of the WHO classification, and the tumours were
classified into four types: (1) infiltrating ductal carcinoma NOS
(not otherwise specified; includes apocrine, mixed mucinous and
atypical medullary types): (2) infiltrating lobular carcinoma with
variants; (3) other special types (includes tubular, medullary, crib-
riform, papillary and pure mucinous carcinomas): and (4) in situ
carcinomas.
DNA flow cytometry
The cellular proliferation rate of cancers was estimated by deter-
mining the size of the S-phase fraction (SPF) using DNA flow
cytometry and paraffin-embedded tissue. Processing of tissue,
DNA staining with propidium iodide and flow cytometry were
carried out with a FacStar flow cytometer (Becton-Dickinson
Immunocytometry Systems, Mountain View, CA, USA) as
described in detail elsewhere (Toikkanen et al, 1989). DNA ploidy
was analysed in 391 (61%) ofthe 639 cases. DNA ploidy analysis
was not carried out in 248 cases because of the small size of the
tumour tissue, lack of representative tumour tissue or presence of
carcinoma in situ only. In 82 cases, S-phase fraction of the cell
cycle (SPF) could not be analysed because of the presence of a
small aneuploid stemline, overlapping stemlines or nuclear debris.
Statistical methods
The frequency tables were analysed with the chi-squared test or
the chi-squared test for a linear trend. For comparison of the SPF,
tumour size and age distributions Mann-Whitney's U-test or the
Kruskal-Wallis analysis of variance was used. Comparison of
SPFs between two groups, after adjusting forprimary tumour size,
was done by two-way analysis of variance. Interactions between
screen-detected cancers, interval cancers, clinical cancers, age
groups and the SPFs, after adjusting for the primary tumour size,
were analysed using a log-linear model. All P-values are two-
tailed. The BMDP computerprogram (BMDP Statistical Software,
Department of Biomathematics, University of California, Los
Angeles, CA, USA) was used for statistical analyses.
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Table 3 Comparison of six clinicopathological features between invasive screen-detected, interval and clinical cancers among women aged 40-74 yearsa
Variable Screen-detected Clinical Interval P
cancers (S) cancers (C) cancers (I)
n (%) n (%) n (%)
Tumour size
3-10 mm 175 (47) 17 (12) 17 (18) SvsC, < 0.0001
11-20 mm 115 (31) 61 (43) 40 (43) Svs 1, < 0.0001
21-30 mm 62 (17) 34 (24) 20 (22) C vs 1, 0.45
>30 mm 22 ( 6) 31 (22) 15 (16) All <0.0001
Axillary nodal status
pNO 309 (80) 87 (57) 63 (64) S vsC, < 0.0001
pN+ 75 (20) 65 (43) 35 (36) S vsl, 0.0007
Cvsl, 0.27
All < 0.0001
Histological type
Ductal 285 (74) 128 (83) 74 (74) S vsC, 0.08
Lobular 63 (16) 17 (11) 18 (18) Svsl, 0.84
Other 37 (10) 9 ( 6) 8 ( 8) C vsl, 0.20
All 0.22
Histological grade
Well 145 (38) 17 (11) 18 (19) SvsC, < 0.0001
Moderate 166 (44) 89 (59) 41 (44) S vs 1, < 0.0001
Poor 66 (18) 46 (30) 35 (37) C vs 1, 0.05
All < 0.0001
DNA ploidy
Diploid 81 (45) 43 (34) 27 (32) S vsC, 0.08
Non-diploid 101 (55) 82 (66) 57 (68) S vsl, 0.06
Cvsl, 0.73
All 0.08
S-phase fraction
<6.0% (median) 86 (62) 44 (44) 27 (38) S vsC, 0.006
> 6.0% (median) 52 (38) 55 (56) 45 (63) S vsl, 0.0006
Cvsl, 0.36
All 0.0009
aData on axillary nodal status, histological grade, the primary tumour size, DNA ploidy and the SPF were not available in 5, 16, 30, 248 and 330 cases
respectively.
RESULTS
By the end of 1994,639 women in the study population were diag-
nosed as having invasive breast carcinoma. In addition, 44 ductal,
nine lobular in situ carcinomas and two cases of Paget's disease
were found. Of the 639 histologically verified invasive breast
cancers found, 385 (60%) were detected in population mammog-
raphy screening. During the same period, 100 women (16%) in the
same cohort were diagnosed with interval cancer, and 154 cancers
(24%) were found outside screening in the same city and the same
age group.
Sixty-seven (18%) of the 382 breast cancers found in screened
women older than 50 were interval cancers, whereas 33 (32%) of
the 103 cancers found among the screened women aged younger
than 50 were interval cancers (P=0.001). Ofthe 33 interval cancers
found among women aged less than 50, 16 were found among
those screened annually and 17 among those screened every third
year (P=0.22, Table 1). Compared with women older than 50,
interval cancers were more common among the women aged less
than 50 ifscreening was carried out annually (27% vs 18% respec-
tively; P=0.08) or if it was performed every third year (39% vs
18%; P=0.0009).
The majority (67%) of the screen-detected cancers were ofpost-
surgical stage I (pTlNOMO) compared with only 34% of the
cancers found outside screening and 45% of the interval cancers
(P<0.0001, Table 2). There was no significant difference in the
frequency of post-surgical stage I cancers between these three
groups among women aged less than 50 (P=0.73) whereas, in
women aged 50 years or more, 71% of the screen-detected
cancers, 30% of clinical cancers and 47% ofinterval cancers were
ofstage I (P<0.0001).
The primary tumour sizes of the screen-detected cancers were
smaller than those of the interval or clinical cancers, and screen-
detected cancers had less often axillary nodal metastases (P<0.001
forall comparisons, Table 3). Screen-detected cancers tended to be
DNA diploid more often than clinical or interval cancers (P=0.08
and 0.06 respectively). Among women aged less than 50 77% of
screen-detected cancers, 71% of interval cancers and 58% ofclin-
ical cancers did not have metastatic axillary nodes (pN0, P=0.08)
whereas, among women older than 50, 81% of screen-detected
cancers, 62% of interval cancers and 57% of the clinical cancers
were node negative (P<0.0001).
There was little difference between interval cancers and clinical
cancers withrespecttothehistological type,theprimary tumoursize,
axillary nodal status orDNAploidy in the entire series (Table 3).
The median S-phase fraction size of the screen-detected cancers
was 5.0% compared with 8.1% in the clinical cancers and 9.0% in
the interval cancers (P<0.000I,Table4),butahigh S-phase fraction
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Table 4 S-phase fraction size in invasive screen-detected cancers, clinical cancers and interval cancers
Subgroup n S-phase fraction (%) P p
Median Mean Range (adjusted for tumour size)
Age 40-74 years
Screen-detected 138 5.0 7.1 1.0-28.0
Clinical 99 8.1 10.5 1.0-33.0
Interval 72 9.0 11.9 2.0-34.0 <0.0001 0.01
Age 40-49 years
Screen-detected 28 6.6 9.0 2.0-28.0
Clinical 27 6.0 10.1 1.0-28.5
Interval 22 8.3 11.9 3.4-30.4 0.29 0.24
Age 50-74 years
Screen-detected 110 5.0 6.7 1.0-28.0
Clinical 72 9.2 10.7 1.7-33.0
Interval 50 10.0 11.9 2.0-34.0 <0.0001 0.01
was also strongly associated with a large tumour size (P<0.0001).
When an adjustment for the tumour size was made, screen-detected
cancers still had smaller S-phase fractions than the interval and clin-
ical cancers (P=0.01), but there was no significant difference in the
SPF size between the interval and clinical cancers. No significant
difference in the SPFs of screen-detected cancers, clinical cancers
and interval cancers was found among women aged 40-49 at the
time ofscreening (P=0.29, Table 4). There was no difference in the
S-phase fraction size between cancers of women younger than 50
and those aged 50 or older (median 7.0% vs 6.0%; range 1.0-30.4%
vs 1.0-34.0% respectively; P=0.13).
DISCUSSION
The present data from a well-defined urban population, in which
mammography screening was carried out using the two-view tech-
nique and the mammograms were read by experienced radiolo-
gists, show that more interval cancers were found among women
younger than 50 years of age than in those aged 50 years. Women
younger than 50 tended to have more frequent interval cancers
than older women even if the screening interval was 1 year in
women younger than 50 and 2 years in women aged 50 or older
(27% vs 18% respectively; P=0.08). Similarly, the frequency of
screen-detected stage I cancers was lower in women younger than
50 than in women aged 50 or older (50% vs 71% respectively;
P=0.0008). These results are in accordance with those of the UK
trial (Moss et al, 1993) in which 28% of women aged 45-54 and
17% of those aged 55-64 were diagnosed as having interval
cancer. In a study carried out in British Columbia, interval cancers
were diagnosed in 37% ofwomen aged 40-49 and in 11% ofthose
aged 50-79 (Burhenne et al, 1994), and similar findings have been
observed in other series (Peeters et al, 1989; Ikeda et al, 1992).
These findings suggest that mammography is less sensitive among
women aged less than 50 years than in those older than 50 years of
age, but breast cancer might also grow more rapidly in premeno-
pausal women than in post-menopausal women, resulting in more
frequent interval cancers.
In the present series, we found little evidence that the more
frequent interval cancers among younger women could be
explained by their greater biological aggressiveness. The SPF size
of cancers of women aged less than 50 years were not higher than
those of older women. If the cancers of women aged 40-49 were
more aggressive than those of older women, they would be
expected to be associated with a shorter survival provided that
treatment is similar. We had already collected the clinicopatholog-
ical data from the great majority of women diagnosed with breast
cancer in Turku between 1945 and 1984 using local hospital
records and the files ofthe Finnish Cancer Registry (Joensuu et al,
1991). In this series, which includes 1039 breast cancers diag-
nosed in the period 1945-84 among women aged 40-74 years and
treated without adjuvant therapy (except for a few cases), there is
no significant difference in survival between women aged 40-49
and those aged 50-74 (P=0.15; long-rank test); this also suggests
that there is no major difference in the biological aggressiveness of
breast cancer between these two age groups.
The sojourn times (time spent in the preclinical but mammo-
graphically detectable phase) of screen-detected breast cancers of
women aged 40-49 have been measured and shown to be shorter
(1.7 years) than those ofwomen aged 50-59 (3.3 years) or those of
women aged 60-69 (3.8 years) (Tabar et al, 1995), suggesting that
breast cancers in younger women grow faster than those in older
women. However, the poorer results obtained by mammography
screening in younger women are likely to be explained, at least
partly, by the lower sensitivity of mammography to detect cancer
in the premenopausal than in the post-menopausal breast
(Sibbering et al, 1995). The average number of acini per lobule
and the number of lobules per microscopic field is higher in
premenopausal breasts than in post-menopausal breasts, and
premeropausal breasts are less translucent in radiographs because
of the smaller fat content (Haagensen et al, 1971; Gram et al,
1995). However, the division at the age of 50 years is arbitrary,
being based on the approximate age at menopause, and there may
be a gradual transition in the usefulness of mammography around
the age of 50 (Margolese 1996).
In conclusion, fewer interval cancers were found among women
aged 50 years or older and screened at 2-year intervals than among
women aged 40-49 years screened at 1-year or at 3-year intervals.
This was not explained by the faster proliferation rate of breast
carcinomas of younger women and, hence, a poorer sensitivity of
mammography among younger women may play a role. These data
suggest that if the screening interval is reduced to 1 year among
women aged less than 50, the numberofinterval cancers decreases,
but mammography screening may still be somewhat less effective
in this age group than among post-menopausal women.
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